Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes

JCI Insight. 2018 Jan 11;3(1):e96968. doi: 10.1172/jci.insight.96968.

Abstract

Background: In type 1 diabetes (T1D), adjuvant treatment with inhibitors of the renin-angiotensin-aldosterone system (RAAS), which dilate the efferent arteriole, is associated with prevention of progressive albuminuria and renal dysfunction. Uncertainty still exists as to why some individuals with long-standing T1D develop diabetic kidney disease (DKD) while others do not (DKD resistors). We hypothesized that those with DKD would be distinguished from DKD resistors by the presence of RAAS activation.

Methods: Renal and systemic hemodynamic function was measured before and after exogenous RAAS stimulation by intravenous infusion of angiotensin II (ANGII) in 75 patients with prolonged T1D durations and in equal numbers of nondiabetic controls. The primary outcome was change in renal vascular resistance (RVR) in response to RAAS stimulation, a measure of endogenous RAAS activation.

Results: Those with DKD had less change in RVR following exogenous RAAS stimulation compared with DKD resistors or controls (19%, 29%, 31%, P = 0.008, DKD vs. DKD resistors), reflecting exaggerated endogenous renal RAAS activation. All T1D participants had similar changes in renal efferent arteroilar resistance (9% vs. 13%, P = 0.37) irrespective of DKD status, which reflected less change versus controls (20%, P = 0.03). In contrast, those with DKD exhibited comparatively less change in afferent arteriolar vascular resistance compared with DKD resistors or controls (33%, 48%, 48%, P = 0.031, DKD vs. DKD resistors), indicating higher endogenous RAAS activity.

Conclusion: In long-standing T1D, the intrarenal RAAS is exaggerated in DKD, which unexpectedly predominates at the afferent rather than the efferent arteriole, stimulating vasoconstriction.

Funding: JDRF operating grant 17-2013-312.

Keywords: Diabetes; Endocrinology; Nephrology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiotensin II / pharmacology
  • Cohort Studies
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / metabolism*
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / physiopathology
  • Female
  • Glycated Hemoglobin / metabolism
  • Humans
  • Infusions, Intravenous
  • Kidney / blood supply
  • Kidney / drug effects
  • Kidney / metabolism
  • Male
  • Middle Aged
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology*
  • Vasoconstriction / drug effects
  • Vasoconstriction / physiology*

Substances

  • Glycated Hemoglobin A
  • Angiotensin II